Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gary i to smell some connection with the cfo going. Like a buyout.possibly over a buck. But not sure. Something is going on.we will know soon.would prefer we get support from pars buyout company and built igxt into a great film producer.and I don't mean Hollywood. We shall see.
Lasers lowenstein is correct.it is a poster not a peer review. They are getting visibility.
Any news on the conference by Pierce?
The guy is in the know.
He may be coming around to oncosec medicals technology. He is very knowledgeable on cancer treatments.A good support from justice would be good for oncosec medical. He definitely did have the goods on advaxis before it took off big time.
just reading how the success of electroporation needs to take three elements into account. electroporation, tumor, bloodvessels.
Any thoughts on plexxicon deal with merck, effect if any with oncs.
Vista Partners Updates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
Marketwired Vista Partners LLC
4 minutes ago
????
Related Quotes
IBB
338.00
0.00%
ONCS
0.2690
+1.51%
iShares Nasdaq Biotechnology? Watchlist
338.000.00(0.00%)
NASDAQTue, May 5, 2015 4:00 PM EDT
The latest big biotech merger is sending this stock up 125% Business Insider 1 hr 36 mins ago
It’s time to start talking about a biotech correction Yahoo Finance Contributors 15 hrs ago
More
SAN FRANCISCO, CA--(Marketwired - May 6, 2015) - Vista Partners announced today that it has updated coverage on OncoSec Medical Inc. (OTCQB: ONCS) ("the Company"), a biopharmaceutical company developing DNA-based intratumoral cancer immunotherapies based in San Diego, CA, and maintains its twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, "There seems to be growing anticipation to learn when and if immunotherapy may become the standard of care for the treatment of certain types of cancer and potentially all types of cancer in the future. On April 29th, 2015, the FDA's panel made a ruling on Amgen's (AMGN) dual-acting cancer vaccine/viral therapy, talimogene laherparepvec (T-Vec) with a convincing 22-1 committee approval. Amgen is a one of the larger holdings in the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). After T-Vec's recent success and with what seems to be a growing trend in immunotherapy, one which is leaning towards utilizing electroporation based on the data ONCS has produced to date, the projected market value for Melanoma therapeutics is anticipated to reach $3.6 billion by 2020 according to MarketWatch." Mr. Silver concludes, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months."
To download a FREE copy of the OncoSec Medical Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
Contact:
First i will state I am long. There are 2 type of ceo in biotechnology. One that sets up a salary company and one that sets up a company for success with failure as a possibility.l always want the latter. I believe punit is the latter. Time unvails the truth. Unfortunately it is to late by then. Such is biotech. I have one stock, igxt that i am pretty certain the ceo is there to develope a great company.I think punit has the same intention, just a riskier field. just my opinoin.
the combo trials with keytruda, are they supposed to be registered at trials.gov?
Any news from the presentation?
April 28 (Reuters) - Bristol-Myers Squibb Co on Tuesday reported first-quarter sales of its new cancer immunotherapy Opdivo that were about half of those for a rival medicine from Merck & Co, and its shares fell 2 percent.
Opdivo, which is used to treat advanced melanoma and was more recently approved to treat a common form of lung cancer, had sales of $40 million in the quarter. Merck on Tuesday said it Keytruda, a similar new drug that helps the immune system to fight cancer, had first quarter sales of $83 million.
"Opdivo sales of $40 million is a little disappointing. We expected $54 million," BMO Capital Markets analyst Alex Arfaei said in a note. Arfaei said he expects a strong Opdivo launch in the much larger lung cancer market as the year progresses.
Bristol is counting on potential multibillion-dollar sales of its immunotherapy cancer drugs to help drive future growth. Yervoy, an older immunotherapy for melanoma, saw sales rise 20 percent to $325 million.
Bristol-Myers posted better-than-expected quarterly results for the quarter, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment.
The U.S. drugmaker said it earned $1.19 billion, or 71 cents per share, in the first quarter. That compared with $937 million, or 56 cents per share, in the year-earlier period.
Excluding special items, Bristol-Myers earned 71 cents per share, well above the average forecast of 51 cents per share, according to Thomson Reuters I/B/E/S. Results were helped by lower spending on marketing and advertising.
Company sales rose 6 percent to $4.04 billion, about $200 million above Wall Street expectations. They would have risen 13 percent if not for the stronger dollar, which lowers the value of sales abroad.
Bristol-Myers raised the lower end of its full-year 2015 profit forecast by five cents, to $1.60 per share, while keeping the higher end at $1.70.
Sales of Abilify rose 3 percent to $554 million, but would have been far lower if not for a recalculation of royalties Bristol-Myers receives from partner Otsuka Holdings Co.
Under a marketing agreement that ended April 20, Bristol-Myers last year recorded sales of Abilify that reflected an estimated 33 percent royalty rate. But in the recent first quarter, Bristol-Myers recorded sales that reflected an actual 50 percent royalty.
Bristol-Myers shares were off $1.25, or 1.9 percent, at $63.91 on the New York Stock Exchange.
i hope its not just punit riding his salary with deception. i am holding on my shares, but are so far not trusting punit with his timelines and fancy talk. imminent for combo. what is imminent. if the combo drags into the fall without a start someone should kick his ass.
Tax rates here in Quebec are the highest in North America.
.35 soon. Had a dream.
wait, i'm with you buddy.still holding on.
Jack you're being sarcastic again. Don't blame you. I am along.Now we are being told combo this year while punit said second quarter after first saying first q.Wish they would align themselves. I believe the doctors are trying to get it just right. But please coordinate yourselfs doctors and punit. The truth I figure is punit buying time stalling till the doctors are ready
does it mean with this new device it overrides the old and we do not have to pay royalties if we succeed to ino?
wonder if we get pop off ino news. seems to validate what oncs is doing with il-12
just a frustrated long. still a believer. i humor myself before going to work. if their science works, which up to now shows it should, the wait will be worth it.good health and wealth to all.
i believe its at 2:30pm eastern time or new york time
Much appreciated for the effort of your writeup. May you be blessed in your Endeavors.
Waitforit53 i have been going through some of your messages. good stuff man. sharp
1l12+15=£
Il15+key=¥¥
Key+il12=€€€€??
Il12+=??
Looks like oncosec medical is on the right track. With electrop oration there is also less toxicity than the iv method
20 bagger my friend.people do not exactly know what they own. electrical impulses. lets see. brain stimulators. defibrulators, pace makers, electroporation.
20 bagger. wait when people realize electroporation's success
20 bagger min!!!!!!!
Oncs 20 bagger!!!!!!
Mms have reversed. People chasing. +stock is undervalued.
What is an investigator Sponsored Trial (IST)?
Generally, Clinical trials can be divided into two groups, according to the type of Sponsor:
The typical industry-sponsored clinical trial, where the trial is conducted by a private entity (who is commonly the holder of the "marketing authorization" of the trial product)
The Investigator Sponsored Trial where the Sponsor is a physical person (physician, nurse, dentist, or other health professional) or a "not-for-profit organization", which can be a governmental body (for example, the National Institute of Health), a public institution (hospital, University, a trust), or a research group.
This Phase II clinical trial will be conducted as a multicenter Investigator Sponsored Trial (IST), with UCSF and Dr. Alain Algazi as the sponsor. Merck will supply pembrolizumab, and OncoSec will provide electroporation devices and plasmid IL-12. Enrollment is expected to begin in Q1 2015.
Market is full of schisters
You are looking at a successful combo. Soon. god bless all cancer patients.